"10.1371_journal.pone.0102517","plos one","2014-07-14T00:00:00Z","Tam Duong; Jaetaek Kim; H Earl Ruley; Daewoong Jo","Department of Biomedical Sciences, Chonnam National University Medical School, Kwangju, Korea; Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Chung-Ang University, Seoul, Korea; Department of Pathology, Microbiology & Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America; ProCell R&D Institute, ProCell Therapeutics, Inc., Seoul, Korea","Conceived and designed the experiments: DJ. Performed the experiments: TD DJ. Analyzed the data: JK HER DJ. Wrote the paper: HER DJ.","Daewoong Jo was the founding scientist of ProCell Therapeutics, Inc., and is affiliated with Vanderbilt University at present. Hereby, Daewoong Jo discloses a financial interest in the company. The other authors disclosed no potential conflicts of interest. ProCell Therapeutics, Inc. has filed a patent for “cell-permeable recombinant parkin protein and a pharmaceutical composition for treating degenerative brain diseases containing the same” under the names of Daewoong Jo, Chanki Kim, Jung-Hee Lim, Yoori Choi, and Hee-Hyun Kim. The relevant application number is PCT/KR2011/007682. There are no further patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.","2014","07","Tam Duong","TD",4,TRUE,1,2,3,2,TRUE,FALSE,FALSE,0,NA,FALSE
